MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Prevalence of Restless Legs Syndrome in hemodialyzed patients

    I. Estrada-Bellmann, S. Castillo-Torres, C. Cerda-Contreras, J. Peña-Avendaño, D. Ortiz-Zacarías (Monterrey, Mexico)

    Objective: To determine the prevalence of restless legs syndrome in patients on hemodialysis. Background: The restless leg syndrome (RLS) is a frequent complication of hemodialysis…
  • 2017 International Congress

    Using measurements from wearable sensors for automatic scoring of Parkinson’s disease motor states

    I. Thomas, F. Bergquist, R. Constantinescu, D. Nyholm, M. Senek, M. Memedi (Falun, Sweden)

    Objective: The aim of this study was to investigate the concurrent validity of an objective gait measure for assessment of motor states in advanced Parkinson’s…
  • 2017 International Congress

    Evaluating the Clinical Efficacy of the Personal KinetiGraph Movement Recording System

    A. Fowler, K. Lyons, V. Sharma, R. Pahwa (Kansas City, KS, USA)

    Objective: To examine the clinical efficacy of the Personal KinetiGraph (PKG) movement recording in identifying patients with Parkinson’s disease (PD) requiring treatment for motor symptoms.…
  • 2017 International Congress

    Design and discovery of 1,2,4 triazole derivatives as adenosine A2A receptor antagonist against parkinson’s disease

    A. Verma, V. Kumar, U. Singh (Allahabad, India)

    Objective: In the present study, we intended to develop novel 1,2,4 triazole as potent A(2A)AR antagonists against parkinson’s disease. Background: Parkinson’s disease (PD) is a…
  • 2017 International Congress

    Intrajejunal levodopa infusion (ILI) for Parkinson’s Disease (PD): A Canadian Experience

    P. Podgorny, P. McCann, K. Toore, G. Tremain, A. Lazarescu, O. Suchowersky (Edmonton, AB, Canada)

    Objective: To review the benefits and complications of ILI for PD in a tertiary movement disorders center in Canada. Background: ILI has been in use…
  • 2017 International Congress

    Botulinum Neurotoxin (BoNT) for treatment of functional (psychogenic) jerky movement disorders: a randomized placebo-controlled clinical trial

    Y. Dreissen, J. Dijk, J. Gelauff, E. Zoons, M. Contarino, R. Zutt, B. Post, D. van Poppelen, A. Munts, J. Speelman, R. de Haan, J. Koelman, M. Tijssen (Amsterdam, Netherlands)

    Objective: To assess the effectiveness of botulinum neurotoxin (BonT) in patients with functional jerky movement disorders Background: At least 2–9% of patients seen in movement…
  • 2017 International Congress

    Treatment of secondary movement disorders related to midbrain cavernomas

    K. Karpinska, A. Smolanka (Uzhgorod, Ukraine)

    Objective: To evaluate possible efficacy and safety of standard antiparkinsonian drugs (levodopa formulations, amantadine) in patients with symptomatic midbrain cavernomas (haemorhage and/or surgery) and secondary…
  • 2017 International Congress

    Essential Tremor and Depression

    S. Aslam, N. Zhang, C. Adler, J. Caviness, E. Driver-Dunckley, S. Mehta, M. Sabbagh, T. Beach, H. Shill (Phoenix, AZ, USA)

    Objective: To determine if depression and neuropsychiatric symptoms are more prevalent in patients with essential tremor (ET) compared with non-ET controls and if so, to establish…
  • 2017 International Congress

    Forehead Tremor: a clinical presentation of ocular Myasthenia Gravis?

    G. Sciacca, E. Reggio, G. Donzuso, A. Nicoletti, M. Zappia (Catania, Italy)

    Objective: The case of a patient with seropositive Myasthenia gravis (MG), presenting with forehead tremor, is reported. Background: The clinical presentation of MG with involuntary movements…
  • 2017 International Congress

    Targeting the intracellular localization of Ataxin-3 as novel treatment strategy for Spinocerebellar Ataxia Type 3

    T. Schmidt, Z. Wang, A. Sowa, J. Schmidt, M. Anders, M.I. Martins, A. de Castro, D. Weishäupl, J. Weber, H. Tricoire, P. Maciel, O. Riess (Tuebingen, Germany)

    Objective: Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph disease (MJD) is an autosomal-dominantly inherited neurodegenerative disorder caused by a CAG expansion in the ATXN3 gene…
  • « Previous Page
  • 1
  • …
  • 118
  • 119
  • 120
  • 121
  • 122
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley